

## DAFTAR PUSTAKA

- [1] H. Sung *et al.*, “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” *CA A Cancer J Clin*, vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.
- [2] F. Bishehsari, M. Mahdavinia, M. Vacca, R. Malekzadeh, and R. Mariani-Costantini, “Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention,” *World J Gastroenterol*, vol. 20, no. 20, pp. 6055–6072, May 2014, doi: 10.3748/wjg.v20.i20.6055.
- [3] Global Cancer Observatory, “Cancer Today in Indonesia,” *The Global Cancer Observatory*, 2020, [Online]. Available: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-%20fact-sheets.pdf>
- [4] P. Rawla, T. Sunkara, and A. Barsouk, “Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors,” *pg*, vol. 14, no. 2, pp. 89–103, 2019, doi: 10.5114/pg.2018.81072.
- [5] I. Mármol, C. Sánchez-de-Diego, A. Pradilla Dieste, E. Cerrada, and M. Rodriguez Yoldi, “Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer,” *IJMS*, vol. 18, no. 1, p. 197, Jan. 2017, doi: 10.3390/ijms18010197.
- [6] A. Recio-Boiles, S. Kashyap, A. Tsoris, and H. M. Babiker, “Rectal Cancer,” in *StatPearls*, Treasure Island (FL): StatPearls Publishing, 2022. Accessed: Feb. 16, 2022. [Online]. Available: <http://www.ncbi.nlm.nih.gov/books/NBK493202/>
- [7] M. C. Garofalo and A. C. Berger, “A PHASE II EVALUATION OF PREOPERATIVE CHEMORADIOTHERAPY UTILIZING INTENSITY MODULATED RADIATION THERAPY (IMRT) IN COMBINATION WITH CAPECITABINE AND OXALIPLATIN FOR PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER,” p. 63.
- [8] M. Hu, L. Jiang, X. Cui, J. Zhang, and J. Yu, “Proton beam therapy for cancer in the era of precision medicine,” *Journal of Hematology & Oncology*, vol. 11, no. 1, p. 136, Dec. 2018, doi: 10.1186/s13045-018-0683-4.
- [9] N. S. Wahyuni and Y. Sardjono, “Assesment of Boron Neutron Capture Therapy (BNCT): Compact Neutron Generators,” *Indonesian Journal of*



*Physics and Nuclear Applications*, vol. 3, no. 2, pp. 36–42, Dec. 2018, doi: 10.24246/ijpna.v3i2.36-42.

- [10] H. Koivunoro, L. Kankaanranta, T. Seppälä, A. Haapaniemi, A. Mäkitie, and H. Joensuu, “Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival,” *Radiotherapy and Oncology*, vol. 137, pp. 153–158, Aug. 2019, doi: 10.1016/j.radonc.2019.04.033.
- [11] C. M. Yashar, “Basic Principles in Gynecologic Radiotherapy,” in *Clinical Gynecologic Oncology*, Elsevier, 2018, pp. 586-605.e3. doi: 10.1016/B978-0-323-40067-1.00023-1.
- [12] S. E. Alex, E. D. Brooks, and E. B. Holliday, “Proton therapy for colorectal cancer,” p. 6, 2019.
- [13] I. Joye and K. Haustermans, “Early and late toxicity of radiotherapy for rectal cancer,” *Recent Results Cancer Res*, vol. 203, pp. 189–201, 2014, doi: 10.1007/978-3-319-08060-4\_13.
- [14] M. Fok *et al.*, “Proton beam therapy in rectal cancer: A systematic review and meta-analysis,” *Surgical Oncology*, vol. 38, p. 101638, Sep. 2021, doi: 10.1016/j.suronc.2021.101638.
- [15] A. B. Benson *et al.*, “Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology,” *J Natl Compr Canc Netw*, vol. 16, no. 7, pp. 874–901, Jul. 2018, doi: 10.6004/jnccn.2018.0061.
- [16] C. Richman, “The physics of cancer therapy with negative pions,” *Med. Phys.*, vol. 8, no. 3, pp. 273–291, May 1981, doi: 10.1118/1.594868.
- [17] G. B. Goodman, L. D. Skarsgard, G. B. Thompson, R. Harrison, G. K. Y. Lam, and C. Lugate, “Pion therapy at TRIUMF. Treatment results for astrocytoma grades 3 and 4: a pilot study,” *Radiotherapy and Oncology*, vol. 17, no. 1, pp. 21–28, Jan. 1990, doi: 10.1016/0167-8140(90)90045-X.
- [18] L. D. Skarsgard, R. M. Henkelman, and C. J. Eaves, “Pions for radiotherapy at TRIUMF,” *J Can Assoc Radiol*, vol. 31, no. 1, pp. 3–12, Mar. 1980.
- [19] M. R. Raju, “NEGATIVE PION BEAMS FOR RADIOTHERAPY,” p. 30, 1974.
- [20] V. Mahadevan, “Anatomy of the rectum and anal canal,” *Surgery - Oxford International Edition*, vol. 38, no. 1, pp. 7–11, Jan. 2020, doi: 10.1016/j.mpsur.2019.10.016.
- [21] J. R. T. Monson, M. R. Weiser, W. D. Buie, G. J. Chang, and J. F. Rafferty, “Practice parameters for the management of rectal cancer (revised),” *Diseases*



*of the Colon and Rectum*, vol. 56, no. 5, pp. 535–550, 2013, doi: 10.1097/DCR.0b013e31828cb66c.

- [22] “NCCN Guidelines for Patients Rectal Cancer,” *Rectal Cancer*, p. 80, 2021.
- [23] M. S. Fazeli and M. R. Keramati, “Rectal cancer: a review,” *Med J Islam Repub Iran*, vol. 29, p. 171, Jan. 2015.
- [24] Y. H. W. Wang and J. Wiseman, “Anatomy, Abdomen and Pelvis, Rectum,” in *StatPearls*, Treasure Island (FL): StatPearls Publishing, 2022. Accessed: Jan. 29, 2022. [Online]. Available: <http://www.ncbi.nlm.nih.gov/books/NBK537245/>
- [25] S. Marecik, J. Park, and L. M. Prasad, “Rectal Anatomy: Clinical Perspective,” in *Rectal Cancer*, G. J. Chang, Ed. Cham: Springer International Publishing, 2018, pp. 1–23. doi: 10.1007/978-3-319-16384-0\_1.
- [26] R. N. Latifah, “KARAKTERISTIK KLINIS PENDERITA KANKER KOLOREKTAL DI INDONESIA – SUATU STUDI LITERATUR,” other, Universitas Hasanuddin, 2020. Accessed: Mar. 09, 2022. [Online]. Available: <http://repository.unhas.ac.id/id/eprint/2090/>
- [27] L. Sherwood, *Introduction to Human Physiology*. Brooks/Cole, 2012. [Online]. Available: <https://books.google.co.id/books?id=weouswEACAAJ>
- [28] J. M. Lee and N. K. Kim, “Essential Anatomy of the Anorectum for Colorectal Surgeons Focused on the Gross Anatomy and Histologic Findings,” *Ann Coloproctol*, vol. 34, no. 2, pp. 59–71, Apr. 2018, doi: 10.3393/ac.2017.12.15.
- [29] B. Oronsky, T. Reid, C. Larson, and S. J. Knox, “Locally advanced rectal cancer: The past, present, and future,” *Seminars in Oncology*, vol. 47, no. 1, pp. 85–92, Feb. 2020, doi: 10.1053/j.seminoncol.2020.02.001.
- [30] E. Moltzer, B. Noordman, N. Renken, and D. Roos, “Determination of Tumor Location in Rectosigmoid Carcinomas: Difficulties in Preoperative Diagnostics,” *GastrointestDisord*, vol. 1, no. 1, pp. 210–219, Feb. 2019, doi: 10.3390/gidisord1010016.
- [31] P. J. C. Devi, N. P. Sriwidayani, and N. P. Ekawati, “KARAKTERISTIK KLINIKOPATOLOGI PASIEN TUMOR KOLOREKTAL YANG MENJALANI BIOPSI KOLONOSKOPI DI RSUP SANGLAH DENPASAR TAHUN 2015-2017,” p. 5.
- [32] R. L. Siegel *et al.*, “Colorectal cancer statistics, 2020,” *CA: A Cancer Journal for Clinicians*, vol. 70, no. 3, pp. 145–164, 2020, doi: 10.3322/caac.21601.



- [33] J. Demb *et al.*, “Risk factors for colorectal cancer significantly vary by anatomic site,” *BMJ Open Gastroenterol*, vol. 6, no. 1, p. e000313, Aug. 2019, doi: 10.1136/bmjgast-2019-000313.
- [34] O. Temelli, “Dosimetric Comparison of Adjuvant Pelvic Radiotherapy for Endometrial Cancer using Intensity-Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT) and Helical Tomotherapy (HT),” *South Clin Ist Euras*, 2019, doi: 10.14744/ejmo.2019.28670.
- [35] J. Shang, W. Kong, Y. Wang, Z. Ding, G. Yan, and H. Zhe, “VMAT planning study in rectal cancer patients,” *Radiation Oncology*, vol. 9, no. 1, p. 219, Oct. 2014, doi: 10.1186/s13014-014-0219-1.
- [36] M. Bockbrader and E. Kim, “Role of intensity-modulated radiation therapy in gastrointestinal cancer,” *Expert Review of Anticancer Therapy*, vol. 9, no. 5, pp. 637–647, May 2009, doi: 10.1586/era.09.16.
- [37] B. Emami, “Tolerance of normal tissue to therapeutic radiation,” *Reports Radiother Oncol*, vol. 1, pp. 35–48, Jan. 2013.
- [38] I. A. T. K. Dewi and S. A. Gondhowiardjo, “Rectal Cancer : A Mini Literature Review,” *Radioter Onkol Indones*, vol. 12, no. 1, pp. 32–39, Oct. 2021, doi: 10.32532/jori.v12i1.115.
- [39] S. HAMILTON, “Carcinoma of the colon and rectum,” *World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System*, pp. 105–119, 2000.
- [40] N. J. Petrelli, A. A. Valle, T. K. Weber, and M. Rodriguez-Bigas, “Adenosquamous carcinoma of the colon and rectum,” *Diseases of the Colon & Rectum*, vol. 39, no. 11, pp. 1265–1268, Nov. 1996, doi: 10.1007/BF02055120.
- [41] F. L. Greene and L. H. Sobin, “The Staging of Cancer: A Retrospective and Prospective Appraisal,” *CA: A Cancer Journal for Clinicians*, vol. 58, no. 3, pp. 180–190, 2008, doi: 10.3322/CA.2008.0001.
- [42] R. D. Rosen and A. Sapra, “TNM Classification,” in *StatPearls*, Treasure Island (FL): StatPearls Publishing, 2022. Accessed: Feb. 16, 2022. [Online]. Available: <http://www.ncbi.nlm.nih.gov/books/NBK553187/>
- [43] M. Mulla, R. Deb, and R. Singh, “MRI in T staging of rectal cancer: How effective is it?,” *Indian Journal of Radiology and Imaging*, vol. 20, no. 02, pp. 118–121, Apr. 2010, doi: 10.4103/0971-3026.63055.
- [44] U. R. D. Simandjuntak, “RASIO PLATELET LIMFOSIT (PLR) DAN RASIO NEUTROFIL LIMFOSIT (NLR) PRE TREATMENT SEBAGAI FAKTOR PROGNOSTIK PASIEN KANKER REKTUM STADIUM III



DAN IV DI RSUP H. ADAM MALIK MEDAN TAHUN 2011-2013,” p. 76, 2018.

- [45] Y. Iwamoto *et al.*, “Benchmark study of the recent version of the PHITS code,” *null*, vol. 54, no. 5, pp. 617–635, May 2017, doi: 10.1080/00223131.2017.1297742.
- [46] T. Sato *et al.*, “Recent Improvements of Particle and Heavy Ion Transport code System: PHITS,” *EPJ Web Conf.*, vol. 153, p. 06008, 2017, doi: 10.1051/epjconf/201715306008.
- [47] H. Ramadan, P. U. Gio, and Elly Rosmaini, “Monte Carlo Simulation Approach to Determine the Optimal Solution of Probabilistic Supply Cost,” *J. of Research in Math. Trends and Tech.*, vol. 2, no. 1, pp. 1–6, Feb. 2020, doi: 10.32734/jormtt.v2i1.3752.
- [48] T. Furuta and T. Sato, “Medical application of particle and heavy ion transport code system PHITS,” *Radiol Phys Technol*, vol. 14, no. 3, pp. 215–225, Sep. 2021, doi: 10.1007/s12194-021-00628-0.
- [49] T. Sato and *et. al*, *User’s Manual: PHITS Ver. 3.26*. Japan Atomic Energy Agency (JAEA), 2021.
- [50] A. Degiovanni and U. Amaldi, “History of hadron therapy accelerators,” *Physica Medica*, vol. 31, no. 4, pp. 322–332, Jun. 2015, doi: 10.1016/j.ejmp.2015.03.002.
- [51] J. S. Welsh, “Basics of Particle Therapy: Introduction to Hadrons,” *American Journal of Clinical Oncology*, vol. 31, no. 5, pp. 493–495, Oct. 2008, doi: 10.1097/COC.0b013e31816a6237.
- [52] P. H. Fowler and D. H. Perkins, “The possibility of therapeutic applications of beams of negative pi-mesons,” *Nature*, vol. 189, pp. 524–528, Feb. 1961, doi: 10.1038/189524a0.
- [53] H. S. Kaplan, H. A. Schwettman, W. M. Fairbank, D. Boyd, and M. A. Bagshaw, “A hospital-based superconducting accelerator facility for negative pi-meson beam radiotherapy,” *Radiology*, vol. 108, no. 1, pp. 159–172, Jul. 1973, doi: 10.1148/108.1.159.
- [54] R. Y. A. Sari, “ANALISIS SIFAT-SIFAT PION DALAM REAKSI INTI DALAM TERAPI PION,” p. 9.
- [55] P. Braun-Munzinger, “Pion Production in Heavy-Ion Collisions,” p. 35.
- [56] W. P. Levin and T. F. DeLaney, “Charged Particle Radiotherapy,” in *Clinical Radiation Oncology*, Elsevier, 2016, pp. 358-372.e2. doi: 10.1016/B978-0-323-24098-7.00019-8.



- [57] J. J. Meyer, B. G. Czito, and C. G. Willett, "Particle Radiation Therapy for Gastrointestinal Malignancies," *Gastrointest Cancer Res*, vol. 1, no. 4 Suppl 2, pp. S50–S59, 2007.
- [58] D. Cussol, "Nuclear Physics and Hadrontherapy," p. 47.
- [59] D. R. Grimes, "Estimation of the oxygen enhancement ratio for charged particle radiation," *Phys. Med. Biol.*, vol. 65, no. 15, p. 15NT01, Aug. 2020, doi: 10.1088/1361-6560/ab9371.
- [60] E. C. Halperin, "Particle therapy and treatment of cancer," *The Lancet Oncology*, vol. 7, no. 8, pp. 676–685, Aug. 2006, doi: 10.1016/S1470-2045(06)70795-1.
- [61] D. C. Hagerman and R. A. ameson, "The Los Alamos Meson Physics Facility Accelerator \*," *Journal of Microwave Power*, vol. 3, no. 2, pp. 75–79, Jan. 1968, doi: 10.1080/00222739.1968.11688671.
- [62] D. A. Swenson, "The Los Alamos Meson Physics Facility," p. 32.
- [63] M. R. Raju, "Particle radiotherapy: historical developments and current status," *Radiat Res*, vol. 145, no. 4, pp. 391–407, Apr. 1996.
- [64] D. K. BEWLEY, "Review of performance of high-LET radiation sources used in clinical applications," in *High-LET Radiations in Clinical Radiotherapy*, G. W. BARENDSEN, J. J. BROERSE, and K. BREUR, Eds. Pergamon, 1979, pp. 105–108. doi: 10.1016/B978-0-08-024383-2.50019-6.
- [65] J. R. Richardson, E. W. Blackmore, G. Dutto, C. J. Kost, G. H. Mackenzie, and M. K. Craddock, "Production of Simultaneous, Variable Energy Beams from the Triumf Cyclotron," *IEEE Trans. Nucl. Sci.*, vol. 22, no. 3, pp. 1402–1407, Jun. 1975, doi: 10.1109/TNS.1975.4327895.
- [66] R. Mohan and D. Grosshans, "Proton therapy – Present and future," *Advanced Drug Delivery Reviews*, vol. 109, pp. 26–44, Jan. 2017, doi: 10.1016/j.addr.2016.11.006.
- [67] T. M. Putnam, H. S. Butler, and J. J. Smith, "Computer Control of the LAMPF Accelerator," p. 8, 1966.
- [68] R. W. Harrison and D. E. Lobb, "A Negative Pion Beam Transport Channel for Radiobiology and Radiation Therapy at TRIUMF," *IEEE Trans. Nucl. Sci.*, vol. 20, no. 3, pp. 1029–1031, 1973, doi: 10.1109/TNS.1973.4327317.
- [69] L. Wisser, "Pion treatment of prostate carcinoma at Paul Scherrer Institute (formerly Swiss Institute for Nuclear Research (SIN)) from 1983 to 1992," *Cancer/Radiothérapie*, vol. 8, no. 2, pp. 88–94, Apr. 2004, doi: 10.1016/j.canrad.2003.12.004.





- [70] W. Parker and H. Patrocinio, "CLINICAL TREATMENT PLANNING IN EXTERNAL PHOTON BEAM RADIOTHERAPY," p. 54.
- [71] A. K. Berthelsen *et al.*, "What's new in target volume definition for radiologists in ICRU Report 71? How can the ICRU volume definitions be integrated in clinical practice?," *Cancer Imaging*, vol. 7, no. 1, pp. 104–116, Jun. 2007, doi: 10.1102/1470-7330.2007.0013.
- [72] L. Greene *et al.*, "Chapter 10 - Role of Imaging in Early-Phase Trials," in *Novel Designs of Early Phase Trials for Cancer Therapeutics*, S. Kummar and C. Takimoto, Eds. Academic Press, 2018, pp. 129–149. doi: 10.1016/B978-0-12-812512-0.00010-5.
- [73] J. H. Hendry, "Radiation biology and radiation protection," *Ann ICRP*, vol. 41, no. 3–4, pp. 64–71, Oct. 2012, doi: 10.1016/j.icrp.2012.06.013.
- [74] K. Ono, "An analysis of the structure of the compound biological effectiveness factor," *Journal of radiation research*, vol. 57, Mar. 2016, doi: 10.1093/jrr/rrw022.
- [75] G. F. Knoll, *Radiation Detection and Measurement*. Wiley, 2000. [Online]. Available: <https://books.google.co.id/books?id=HKBVAAAAMAAJ>
- [76] J. Grillenberger, C. Baumgarten, and M. Seidel, "The High Intensity Proton Accelerator Facility," *SciPost Physics Proceedings*, vol. 5, Sep. 2021, doi: 10.21468/SciPostPhysProc.5.002.
- [77] D. Krstić and D. Nikezić, "Input files with ORNL—mathematical phantoms of the human body for MCNP-4B," *Computer Physics Communications*, vol. 176, no. 1, pp. 33–37, Jan. 2007, doi: 10.1016/j.cpc.2006.06.016.
- [78] T. C. Frøseth, T. Strickert, K. S. Solli, Ø. Salvesen, G. Frykholm, and R. J. Reidunsdatter, "A randomized study of the effect of patient positioning on setup reproducibility and dose distribution to organs at risk in radiotherapy of rectal cancer patients," *Radiation Oncology*, vol. 10, no. 1, p. 217, Oct. 2015, doi: 10.1186/s13014-015-0524-3.
- [79] Y. Yang, S. Cai, T. Zhao, Q. Peng, J. Qian, and Y. Tian, "Effect of prone and supine treatment positions for postoperative treatment of rectal cancer on target dose coverage and small bowel sparing using intensity-modulated radiation therapy," *Translational Cancer Research*, vol. 9, no. 2, Feb. 2020, doi: 10.21037/tcr.2019.11.33.
- [80] A. O'Shea and M. G. Harisinghani, "Update on MRI of Rectal Cancer," *Advances in Clinical Radiology*, vol. 3, pp. 1–13, Sep. 2021, doi: 10.1016/j.yacr.2021.04.003.



- [81] S. Aras, O. Tanzer, and T. Ikizceli, “Comparison of Dose Distribution Effects for Various Bolus Materials in Electron Conformal Radiotherapy,” *Celal Bayar Üniversitesi Fen Bilimleri Dergisi*, vol. 16, pp. 201–205, Jan. 2020, doi: 10.18466/cbayarfbe.654782.
- [82] H.-G. Menzel, C. Clement, and P. DeLuca, “ICRP Publication 110. Realistic reference phantoms: an ICRP/ICRU joint effort. A report of adult reference computational phantoms,” *Ann ICRP*, vol. 39, no. 2, pp. 1–164, 2009, doi: 10.1016/j.icrp.2009.09.001.
- [83] H. K. Agusnin, A. Widi Harto, and Y. Sardjono, “Analisis Dosis Boron Neutron Capture Therapy (BNCT) pada kanker kolon dengan Particle and Heavy Ion Treansport Code System (PHITS),” Universitas Gadjah Mada, Yogyakarta, 2021.
- [84] R. L. Maughan, P. J. Chuba, A. T. Porter, E. Ben-Josef, and D. R. Lucas, “The elemental composition of tumors: Kerma data for neutrons,” *Med. Phys.*, vol. 24, no. 8, pp. 1241–1244, Aug. 1997, doi: 10.1118/1.598144.
- [85] K. M. Purwantoro, A. Widi Harto, and Y. Sardjono, “ANALISIS DISTRIBUSI DOSIS RADIASI PADA TERAPI KANKER SERVIKS DENGAN BORON NEUTRON CAPTURE CANCER THERAPY MENGGUNAKAN MCNPX,” Universitas Gadjah Mada, Yogyakarta, 2016.
- [86] R. M. Jr, C. Gesh, R. Pagh, R. Rucker, and R. W. Iii, “Compendium of Material Composition Data for Radiation Transport Modeling,” p. 375.
- [87] N. Tsoulfanidis and S. Landsberger, *MEASUREMENT & DETECTION of RADIATION*, 4th ed. Boca Raton: Taylor & Francis Group, LLC, 2015.
- [88] A. Kern, C. Bäumer, K. Kröninger, J. Wulff, and P. Timmermann, “Impact of air gap, range shifter, and delivery technique on skin dose in proton therapy,” *Medical Physics*, vol. 48, Dec. 2020, doi: 10.1002/mp.14626.
- [89] M. Ilham, A. Widi Harto, and Y. Sardjono, “Analisis Dosis dan Waktu Iradiasi Terapi Proton Pada Kanker Serviks Menggunakan PHITS,” Universitas Gadjah Mada, Yogyakarta, 2022.

